Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. 2005

Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
Division of Clinical Pharmacology and Toxicology, Department of Medicine, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA.

In this study, we demonstrate that angiotensin II (Ang II) protects dopamine (DA) neurons from rotenone toxicity in vitro. Primary ventral mesencephalic (VM) cultures from E15 rats were grown for 5 days and then cultured in the presence of the mitochondrial complex I inhibitor, rotenone. Acute exposure (20 h) to 20 nM rotenone reduced the number of tyrosine hydroxylase-positive (TH+) neurons by 50 +/- 6% when compared to untreated cultures. Pre-treatment of VM cultures with 100 nM Ang II decreased TH+ neuronal loss to 25 +/- 10% at the 20-nM rotenone concentration. Ang II in the presence of the angiotensin type 1 receptor (AT1R) antagonist, losartan, was even more effective in protecting DA neurons showing a loss of only 13 +/- 4% at 20 nM rotenone. Conversely, the AT2R antagonist, PD123319, abolished the protective effects of Ang II. Furthermore, both the NMDA receptor antagonist, MK801, and the antioxidant, alpha-tocopheryl succinate (vitamin E analogue), prevented rotenone-induced toxicity. Here, we show that acute exposure of VM cultures to the pesticide rotenone leads to dopaminergic neuronal cell death and that angiotensin acting through the AT2 receptor protects dopamine neurons from rotenone toxicity.

UI MeSH Term Description Entries
D007306 Insecticides Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. Insecticide
D009410 Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways. Neuron Degeneration,Degeneration, Nerve,Degeneration, Neuron,Degenerations, Nerve,Degenerations, Neuron,Nerve Degenerations,Neuron Degenerations
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
January 2015, Folia neuropathologica,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
January 2015, Folia neuropathologica,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
May 2009, Phytotherapy research : PTR,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
January 2010, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
January 2012, Journal of molecular neuroscience : MN,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
April 1994, Brain research,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
October 2012, Journal of molecular biology,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
August 2010, Journal of neuroimmunology,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
January 2006, Journal of neurochemistry,
Tom N Grammatopoulos, and Ferogh Ahmadi, and Susan M Jones, and Marc W Fariss, and James A Weyhenmeyer, and W Michael Zawada
July 1994, Neuroscience letters,
Copied contents to your clipboard!